14022 Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices 

SUMMARY: The Office of the Surgeon 

General published a document in the 

Federal Register of March 7, 2022, 

requesting information regarding the 

Impact of Health Information 

Misinformation in the Digital 

Information Environment in the United 

States Throughout the COVID–19 

Pandemic. The document included a 

hyperlink in which the public will not 

be able to access. 

FOR FURTHER INFORMATION CONTACT: Max 

Lesko at COVIDMisinfoRFI@hhs.gov or 

at (202) 893–5020. 

SUPPLEMENTARY INFORMATION: 

Correction 

In the Federal Register of March 7, 

2022, in FR Doc. 2022–04777, on page 

12713, in the third column, correct the 

section which reads, ‘‘a. Starting with, 

but not limited to, these common 

examples of COVID–19 vaccine 

misinformation documented by the 

Centers for Disease Control and 

Prevention (CDC), any aggregate data 

and analysis on the prevalence of 

COVID–19 misinformation on 

individual platforms including exactly 

how many users saw or may have been 

exposed to instances of COVID–19 

misinformation.’’ to read, ‘‘a. Starting 

with but not limited to https://

www.cdc.gov/coronavirus/2019-ncov/ 

vaccines/facts.html of COVID–19 

vaccine misinformation documented by 

the Centers for Disease Control and 

Prevention (CDC), any aggregate data 

and analysis on the prevalence of 

COVID–19 misinformation on 

individual platforms including exactly 

how many users saw or may have been 

exposed to instances of COVID–19 

misinformation.’’ 

Max Lesko, 

Chief of Staff, Office of the Surgeon General. 

[FR Doc. 2022–05132 Filed 3–10–22; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; American Women: 

Assessing Risk Epidemiologically (AWARE) 

(R01 Clinical Trial Optional). 

Date: April 5, 2022. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G22B, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Kristina S. Wickham, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G22B, 

Rockville, MD 20852, 301–761–5390, 

kristina.wickham@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: March 7, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05136 Filed 3–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK Data 

Coordinating Center. 

Date: April 5, 2022. 

Time: 12:30 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health/NIDDK, 

6707 Democracy Blvd., Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Elena Sanovich, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7351, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–8886, 

sanoviche@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: March 7, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05135 Filed 3–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Fusion Proteins 

for the Treatment of Growth Disorders 

and Diseases of Cartilage 

Degeneration 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development and the National 

Cancer Institute, both institutes of the 

National Institutes of Health, 

Department of Health and Human 

Services, are contemplating the grant of 

an Exclusive Patent License to practice 

the inventions embodied in the Patents 

and Patent Applications listed in the 

Supplementary Information section of 

this Notice to Cavalry Biosciences, Inc. 

of San Francisco, CA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before March 28, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Richard T. Girards, Jr., Esq., 

MBA, Senior Technology Transfer 

Manager, National Institutes of Health, 


lotter on DSK11XQN23PROD with NOTICES1